skip to main content

TARGET: Acute Myeloid Leukemia (AML)

Identifiers: SRA: SRP012000
BioProject: PRJNA89525
dbGaP: phs000465
Study Type: 
Other
Submission: SRA051357 on 2012-03-30 14:01:00
Abstract: There are 200+ fully characterized patient cases with AML (all tumor/normal pairs, 100 with relapse sample as well) that make up the TARGET AML dataset, each with gene expression, tumor and paired normal copy number analyses, methylation and comprehensive next-generation sequencing to include whole genome sequencing, mRNA-seq and miRNA-seq. A subset of these cases will also have whole exome sequencing data available as well. There are additionally a large number of cases with partial molecular characterization making this a large and informative genomic dataset. Additionally, the TARGET AML cohort includes some highly aggressive subtypes including AML "induction failures." Upon diagnosis, AML patients without high-risk genetic markers undergo standard chemotherapy, called the primary induction phase. This phase lasts about 30 days and is designed to eliminate cancer cells. Success of treatment is measured by the percentage of myeloblasts, i.e. immature... (for more see dbGaP study page.)

The SRA runs contain human sequence

These data are available through the dbGaP authorized access system.

Related SRA data

Experiments:
4569
Runs:
4858 (165.8Tbp; 106.5Tb)